Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy

Introduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, altho...

Full description

Autores:

Barrón-Barrón, Feliciano
Sánchez, Roberto P.
Arroyo-Hernández, Marisol
Blanco, Carolina
Zatarain-Barrón, Zyanya Lucia
Catalán, Rodrigo
Ramos-Ramírez, Maritza
Cardona-Mendoza, Andrés Felipe
Flores-Estrada, Diana
Arrieta, Oscar

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/5058

Acceso en línea:

http://hdl.handle.net/20.500.12495/5058
https://doi.org/10.3389/fonc.2020.570233

Palabra clave:

Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects

Rights

openAccess

License

Attribution 4.0 International